AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03615937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhancement to the kindergartens
Description: This intervention package aims at providing a better physical and social kindergarten environment to maximize developmental reach and expedite timely interception and feedback without adding burden to teachers and frontline service professionals.
Study NCT03615937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education, screening, and support
Description: Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
Study NCT03615937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education, screening, and support
Description: Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
Study NCT02782624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 5 days of treatment with 5 mg BI 10773 bid until steady state
Study NCT02782624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 5 days of treatment with 10 mg BI 10773 qd until steady state
Study NCT01496040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2/4.hRPE65
Description: One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP.
Study NCT01523964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Testing with EIM
Study NCT04251052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04251052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04251052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04251052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04251052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal Ultrasound
Description: Undergo transvaginal ultrasound
Study NCT04251052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal Ultrasound
Description: Undergo transvaginal ultrasound
Study NCT04251052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo pelvic ultrasound
Study NCT04251052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Imaging
Description: Undergo pelvic ultrasound
Study NCT01364051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study NCT01364051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT01364051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01364051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01364051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT01364051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT03655340 — intervention group
Intervention type: DRUG
Intervention: Alprolix
Description: Extended half-life factor IX product
Study NCT04539496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: * 20-560 mg QD, oral~* 240-480 mg BID, oral
Study NCT04539496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287;Letrozole;Anastrozole;Fulvestrant
Description: XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)
Study NCT04539496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: 480 mg BID, oral
Study NCT02588690 — intervention group
Intervention type: PROCEDURE
Intervention: Fingerstick cholesterol test
Description: A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
Study NCT02588690 — intervention group
Intervention type: OTHER
Intervention: Atherosclerosis Cardiovascular Disease Risk assessment
Description: This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol \<190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status.
Study NCT02588690 — intervention group
Intervention type: PROCEDURE
Intervention: Blood pressure measurement
Description: Blood pressure measurement
Study NCT00207155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
Study NCT01874639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard bipolar coagulation
Study NCT01874639 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aquamantys® probe for liver hemostasis
Study NCT04038359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Phosphoinositide 3-kinase (PI3K) inhibitor
Study NCT01766609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study NCT01281618 — intervention group
Intervention type: PROCEDURE
Intervention: 24 hour pH study and upper endoscopy (EGD)
Description: All subjects enrolled will undergo 24 hour pH followed by EGD.
Study NCT04332822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-pola-mini-CHP
Description: * Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~* Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~* Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~* Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~* Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6
Study NCT04332822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mini-CHOP
Description: * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
Study NCT02381600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Experimental :~1. Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~2. Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~3. At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.
Study NCT03893071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl-β-cyclodextrin
Description: HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
Study NCT02955589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000
Description: Oral, twice weekly
Study NCT02738801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690 600 mg QD
Description: GLPG1690 capsules, administered at a dose of 600 mg, orally QD
Study NCT02738801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo QD
Description: Matching placebo capsules, administered orally QD
Study NCT02971917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest x-ray image acquisition
Description: Obtain a digital X-ray chest image of the patient
Study NCT02971917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Creation of TRUVIEW ART applied image
Description: Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.~Outcome: 2 versions of chest image~1. Original Chest X-ray (w/o TRUVIEW ART)~2. TRUVIEW ART applied image
Study NCT02971917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Comparison of TRUVIEW ART image with original image
Description: Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
Study NCT03207126 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound guided biopsy
Description: For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
Study NCT04069559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To develop nursing students' attitudes towards refugees program which based on contact hypothesis.
Description: In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
Study NCT01025908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Cognitive Behavioral Therapy
Study NCT01025908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportative psychotherapy
Description: Supportative psychotherapy
Study NCT02411630 — intervention group
Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil
Description: ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed.
Study NCT02244541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Oral
Study NCT02244541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Intravenous
Study NCT02244541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Oral
Description: 30 mg hard gelatin capsule
Study NCT02244541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Oral
Description: 50 mg hard gelatin capsule
Study NCT02638116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
Study NCT02638116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
Study NCT03482622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fast Raman
Description: Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
Study NCT02859922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube Suction Disposable
Description: Laryngeal Tube Suction Disposable
Study NCT02859922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme Laryngeal Mask Airway
Description: Supreme Laryngeal Mask Airway
Study NCT00771914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg tablet
Study NCT00771914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza 4 grams
Study NCT00771914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Both Aspirin and Lovaza
Description: Lovaza 4 grams plus aspirin 81 mg
Study NCT00771914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule resembling fish oil and a tablet resembling aspirin
Study NCT01003301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
Study NCT01003301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
Study NCT04045860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy
Description: A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
Study NCT04045860 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Standard of care is currently observation
Study NCT04937985 — intervention group
Intervention type: OTHER
Intervention: Performance Tests
Description: Performance tests consist of Six Minute Pegboard Ring Test, 30-Second Push-Up Test and Arm, Shoulder and Hand Injury Questionnaire (DASH), Neck Disability Index, New York Posture Rating Chart and Short Form-36 Health Survey.
Study NCT05288816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
Study NCT02300207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic acupuncture treatment instrument
Description: Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
Study NCT04637568 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized tomography
Description: Obtained CT scans involving the head region were analyzed retrospectively.
Study NCT03416868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory voice biofeedback
Description: Patients will be provided cues regarding their vocal behavior in daily life. Specifically, the patient will receive 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly. The specific objective voice measure for biofeedback will depend upon which measure is most strongly associated with improvements during voice therapy.
Study NCT02989493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Doxazosin
Study NCT02989493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01950416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg loading dose and 90mg bid maintenance dose
Study NCT01950416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 600mg loading dose and 150mg maintenance dose
Study NCT01710345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab 20 mcg
Study NCT01710345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab 30 mcg
Study NCT01710345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo NanoTab
Study NCT03982901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Mental Stress Test
Description: In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.
Study NCT03982901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mental Stress Test
Description: In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.
Study NCT04475081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: Merck MMR-II vaccine
Study NCT04475081 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MMR vaccine
Description: Merck MMR-II vaccine
Study NCT04479397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet Surgery for anterior shoulder instability
Description: Bone block procedure for anterior shoulder instability
Study NCT04479397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet Surgery for anterior shoulder instability
Description: Bone block procedure for anterior shoulder instability
Study NCT04479397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No sling in postoperative care
Description: No sling will be used in postoperative care.
Study NCT05213832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane Inhal Soln
Description: Administration of isofluorane in patients with severe SAH
Study NCT00704210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpineMed Table, Cert HealthSciences LLC
Description: For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
Study NCT00704210 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SpineMed Table, Cert HealthSciences LLC
Description: Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
Study NCT04011540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital data
Description: Receiving digital data prior to a scheduled mental health session
Study NCT02236026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supratherapuetic dose of Nestorone
Study NCT02236026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02236026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study NCT00774371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy CBT) for weight loss
Description: The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
Study NCT01245309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scratching
Description: endometrial scratching before COH in IVF
Study NCT01245309 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: A PLACEBO PROCEDURE
Description: A PLACEBO PROCEDURE
Study NCT01245309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A PLACEBO PROCEDURE
Description: A PLACEBO PROCEDURE